midpage
Projects
Sign in to see your projects.
41 F. Supp. 3d 323
S.D.N.Y.
2014
Read the full case

Background

  • This is a qui tam FCA action in which the United States intervened against Novartis alleging kickbacks to promote Myfortic and Exjade.
  • The AKS prohibits offering, paying, soliciting, or receiving remuneration to induce purchases of drugs covered by federal programs.
  • The government asserts nine FCA counts (A,B,C for each drug) plus related state-law claims (unjust enrichment and payment by mistake).
  • Pharmacies (not named defendants) allegedly received cash rebates and patient referrals in exchange for promoting the drugs.
  • Novartis moved to dismiss for failure to plead falsity under Rule 12(b)(6) and for fraud with particularity under Rule 9(b); the court previously deferred ruling on 9(b).
  • The court’s decision addresses whether the government’s theory of falsity, particularly Mikes and the 2010 AKS amendment (PPACA § 1320a-7b(g)), supports dismissal or requires repleading.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Does the 2010 AKS amendment supersede Mikes false-certification theory? Government argues amendment clarifies, not narrows, Mikes framework. Novartis argues amendment narrows falsity to post-2010, claim-by-claim causation. Amendment does not narrow Mikes; Mikes remains controlling.
Are express AKS certifications sufficient to render claims false under Part B/Part D/New York Medicaid? Express certifications (CMS Form 855S and subcontracts) render AKS noncompliance false. Certifications may not require causation; argument partially contested. Express certifications render Myfortic (Part B) and Exjade (Part D) claims false.
Can implied certifications render claims false for post-2010 claims? Post-2010 implied certification of AKS compliance makes claims false. Implied false certifications require precondition to payment stated by statute/regulation. Post-2010 implied certifications render claims false; pre-2010 claims require express certifications (or different basis) to survive.
Do state Medicaid claims (beyond New York) survive on express/implied certification theories? States’ express/implied certifications may render many Medicaid claims false. Insufficient pleadings for non-New York states pre-2010; may require repleading. Counts related to non-New York Medicaid pre-2010 dismissed without prejudice; remaining post-2010 viable.
Should state-law claims be dismissed if federal claims are dismissed? Federal and state claims jointly asserted. Court should decline supplemental jurisdiction if federal claims fail. State-law claims survive; court will retain supplemental jurisdiction.

Key Cases Cited

  • Mikes v. Straus, 274 F.3d 687 (2d Cir.2001) (defines ‘false or fraudulent’ claim as one aimed at extracting government payment; split into factual and legal falsity; false certification theory stems here)
  • United States ex rel. Kirk v. Schindler Elevator Corp., 601 F.3d 94 (2d Cir.2010) (reaffirms false certification theory of legal falsity under Mikes)
  • U.S. ex rel. Wilkins v. United Health Group, Inc., 659 F.3d 295 (3d Cir.2011) (adopts false certification approach across circuits in AKS contexts)
  • Hutcheson v. Blackstone Med., Inc., 647 F.3d 377 (1st Cir.2011) (treats AKS compliance as precondition to payment for purposes of FCA falsity)
Read the full case

Case Details

Case Name: United States ex rel. Kester v. Novartis Pharmaceuticals Corp.
Court Name: District Court, S.D. New York
Date Published: Aug 7, 2014
Citations: 41 F. Supp. 3d 323; 2014 U.S. Dist. LEXIS 119882; 2014 WL 4230386; No. 11 Civ. 8196(CM)
Docket Number: No. 11 Civ. 8196(CM)
Court Abbreviation: S.D.N.Y.
Log In